JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 24, 2008; DOI: 10.1124/jpet.107.132100


0022-3565/08/3251-69-76$20.00
JPET 325:69-76, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.132100v1
325/1/69    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Katayama, N.
Right arrow Articles by Otagiri, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katayama, N.
Right arrow Articles by Otagiri, M.
Right arrowPubmed/NCBI databases
*Substance via MeSH

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Design and Evaluation of S-Nitrosylated Human Serum Albumin as a Novel Anticancer Drug

Naohisa Katayama, Keisuke Nakajou, Hisakazu Komori, Kunitoshi Uchida, Jun-ichi Yokoe, Norikiyo Yasui, Hisashi Yamamoto, Toshiya Kai, Makoto Sato, Takenobu Nakagawa, Motohiro Takeya, Toru Maruyama, and Masaki Otagiri

Departments of Biopharmaceutics (N.K., H.K., T.K., M.O.) and Clinical Pharmaceutics (T.M.), Graduate School of Pharmaceutical Sciences, and Department of Cell Pathology (T.N., M.T.), Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; and Pharmaceutical Research Center, Nipro Corporation, Shiga, Japan (N.K., K.N., K.U., J.-i.Y., N.Y., H.Y., T.K., M.S.)

In recent studies, the cytotoxic activity of NO has been investigated for its potential use in anticancer therapies. Nitrosated human serum albumin (NO-HSA) may act as a reservoir of NO in vivo. However, there are no published reports regarding the effects of NO-HSA on cancer. Therefore, the present study investigated the antitumor activity of NO-HSA. NO-HSA was prepared by incubating HSA, which had been sulfhydrylated using iminothiolane, with isopentyl nitrite (6.64 mol NO/mol HSA). Antitumor activity was examined in vitro using murine colon 26 carcinoma (C26) cells and in vivo using C26 tumor-bearing mice. Exposure to NO-HSA increased the production of reactive oxygen species in C26 cells. Flow cytometric analysis using rhodamine 123 showed that NO-HSA caused mitochondrial depolarization. Activation of caspase-3 and DNA fragmentation were observed in C26 cells after incubation with 100 µM NO-HSA for 24 h, and NO-HSA inhibited the growth of C26 cells in a concentration-dependent manner. The growth of C26 tumors in mice was significantly inhibited by administration of NO-HSA compared with saline and HSA treatment. Immunohistochemical analysis of tumor tissues demonstrated an increase in terminal deoxynucleotidyl transferase dUTP nickend labeling-positive cells in NO-HSA-treated mice, suggesting that inhibition of tumor growth by NO-HSA was mediated through induction of apoptosis. Biochemical parameters (such as serum creatinine, blood urea nitrogen, aspartate aminotransferase, and alanine aminotransferase) showed no significant differences among the three treatment groups, indicating that NO-HSA did not cause hepatic or renal damage. These results suggest that NO-HSA has the potential for chemopreventive and/or chemotherapeutic activity with few side effects.


Received September 26, 2007; accepted January 23, 2008.

Address correspondence to: Dr. Masaki Otagiri, Department of Biopharmaceutics, Graduate school of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862-0973, Japan. E-mail: otagirim{at}gpo.kumamoto-u.ac.jp







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.